News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Biothera Launches Clinical Trial in KRAS-Mutated Colorectal Cancer Patients
June 10, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
EAGAN, Minn.--(BUSINESS WIRE)--Biothera has initiated a Phase II clinical trial in stage IV KRAS-mutated colorectal cancer patients with its investigational drug Imprime PGG® in combination with Erbitux® (cetuximab), the company announced today.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Neuroscience
NervGen’s Peptide Achieves Nervous System Repair in Phase II Spinal Cord Injury Study
November 24, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Bayer Sets Up Redemption Arc for Anticoagulant With ‘Surprisingly Positive’ Phase III Data
November 24, 2025
·
2 min read
·
Tristan Manalac
Multiple sclerosis
J&J, Contineum Fail ‘Risky’ Mid-Stage Multiple Sclerosis Trial
November 21, 2025
·
2 min read
·
Tristan Manalac
Drug Development
CRO Boom in APAC region, With China at the Forefront
November 19, 2025
·
5 min read
·
Jennifer Smith-Parker
